Search
Streptococcus pneumoniae type 5 capsular polysaccharide antigen
go.drugbank.com/drugs/DB10323ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer FertigspritzeStreptococcus pneumoniae type 23f capsular polysaccharide antigen
go.drugbank.com/drugs/DB10340ApprovedInvestigationalIt is an active immunization for intramuscular or subcutaneous injection against pneumococcal disease such as pneumococcal pneumonia and pneumococcal bacteremia.
Mixtures: SYNFLORIX 0,5 ML IM ENJ. ICIN SUS.ICEREN KUL.HAZIR ENJEKTOR, PNEUMOVAX 23 Injektionslösung in einer FertigspritzeLevoketoconazole
go.drugbank.com/drugs/DB05667ApprovedIt possesses most of the inhibitory effect towards steroidogenic enzymes, making it an attractive candidate for CS treatment with a potentially lower toxicity profile than its racemate. … Still, toxicity has limited its use, notably hepatic toxicity and a tendency to prolong the QT interval.[A244083] Levoketoconazole is one of two enantiomers present in racemic [ketoconazole].
Glucarpidase
go.drugbank.com/drugs/DB08898ApprovedInvestigationalIt prevents methotrexate toxicity in patients with renal dysfunction who are undergoing high-dose methotrexate treatment, as it provides an alternative non-renal pathway for methotrexate elimination. … [L39855] Glucarpidase was first approved by the FDA in January 2012,[A7476] followed by the European Commission's approval in January 2022.[L39865] It is marketed as VORAXAZE.
Picosulfuric acid
go.drugbank.com/drugs/DB09268ApprovedInvestigationalThe combination product containing sodium picosulfate and magnesium citrate was introduced to the Canadian market in 2005 and has been used in European countries for many years.[A33322] … Picosulfuric acid is found in laxative products. Sodium picosulfate is a used to treat constipation or induce colon cleansing to prepare the large bowels before colonoscopy or surgery.
Mixtures: PICOPREP 10 MG / 3,5 G /12 G ORAL ÇÖZELTI IÇIN TOZ, 2 SAŞEProducts: Laxapico 2,5 mg Yumuşak Kapsül, 50 adet, MOTILAXIL-TOrforglipron
go.drugbank.com/drugs/DB18964ApprovedInvestigational[L56123] On April 1, 2026, the US FDA granted approval to orforglipron for use alongside diet and exercise to aid in weight reduction in certain patient populations. … [L56122,L56123] It was the first new molecular entity approved under the Commissioner’s National Priority Voucher (CNPV) pilot program, achieving a regulatory decision just 50 days after filing.
Omalizumab
go.drugbank.com/drugs/DB00043ApprovedInvestigationalOmalizumab is a recombinant DNA-derived humanized monoclonal antibody directed against human immunoglobulin E (IgE). … By binding to IgE and neutralizing it, omalizumab reduces free IgE levels and prevents IgE from binding to its receptors on immune cells.
Products: XOLAIR ® 150 MG, XOLAIR 150 MG ENJEKSIYONLUK COZELTI İÇİN TOZ İÇEREN FLAKON, 1 ADETPolythiazide
go.drugbank.com/drugs/DB01324Approved(From Martindale, The Extra Pharmacopoeia, 30th ed, p826)
Iptacopan
go.drugbank.com/drugs/DB16200ApprovedInvestigational[A262566] Factor B is a positive regulator of the alternative complement pathway, where it activates C3 convertase and subsequently C5 convertase. … [A262581] On December 6th, 2023, Iptacopan under the brand name Fabhalta was approved by the FDA for the treatment of adults with PNH.
Categories: Compounds used in a research, industrial, or household settingCilgavimab
go.drugbank.com/drugs/DB16393ApprovedInvestigationalCilgavimab, in combination with [tixagevimab], was issued an FDA emergency use authorization (EUA) on December 9, 2021, for the pre-exposure prophylaxis of COVID-19 in individuals at increased risk for … [L39411] EVUSHELD was granted marketing authorization by the EMA on March 28, 2022,[L41454] and was approved in Canada soon after, on April 14, 2022.